Imperial College London
Portrait Picture

ProfessorAlanWinston

Faculty of Medicine, Department of Infectious Disease

Professor of Genito-Urinary Medicine
 
 
 
//

Contact

 

+44 (0)20 3312 1603a.winston

 
 
//

Location

 

Winston Churchill WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ogbe:2022:10.1172/jci.insight.157031,
author = {Ogbe, A and Pace, M and Bittaye, M and Tipoe, T and Adele, S and Alagaratnam, J and Aley, PK and Ansari, MA and Bara, A and Broadhead, S and Brown, A and Brown, H and Cappuccini, F and Cinardo, P and Dejnirattisai, W and Ewer, KJ and Fok, H and Folegatti, PM and Fowler, J and Godfrey, L and Goodman, AL and Jackson, B and Jenkin, D and Jones, M and Longet, S and Makinson, RA and Marchevsky, NG and Mathew, M and Mazzella, A and Mujadidi, YF and Parolini, L and Petersen, C and Plested, E and Pollock, KM and Rajeswaran, T and Ramasamy, MN and Rhead, S and Robinson, H and Robinson, N and Sanders, H and Serrano, S and Tipton, T and Waters, A and Zacharopoulou, P and Barnes, E and Dunachie, S and Goulder, P and Klenerman, P and Screaton, GR and Winston, A and Hill, AVS and Gilbert, SC and Carroll, M and Pollard, AJ and Fidler, S and Fox, J and Lambe, T and Frater, J},
doi = {10.1172/jci.insight.157031},
journal = {JCI Insight},
pages = {1--18},
title = {Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV},
url = {http://dx.doi.org/10.1172/jci.insight.157031},
volume = {7},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
AU  - Ogbe,A
AU  - Pace,M
AU  - Bittaye,M
AU  - Tipoe,T
AU  - Adele,S
AU  - Alagaratnam,J
AU  - Aley,PK
AU  - Ansari,MA
AU  - Bara,A
AU  - Broadhead,S
AU  - Brown,A
AU  - Brown,H
AU  - Cappuccini,F
AU  - Cinardo,P
AU  - Dejnirattisai,W
AU  - Ewer,KJ
AU  - Fok,H
AU  - Folegatti,PM
AU  - Fowler,J
AU  - Godfrey,L
AU  - Goodman,AL
AU  - Jackson,B
AU  - Jenkin,D
AU  - Jones,M
AU  - Longet,S
AU  - Makinson,RA
AU  - Marchevsky,NG
AU  - Mathew,M
AU  - Mazzella,A
AU  - Mujadidi,YF
AU  - Parolini,L
AU  - Petersen,C
AU  - Plested,E
AU  - Pollock,KM
AU  - Rajeswaran,T
AU  - Ramasamy,MN
AU  - Rhead,S
AU  - Robinson,H
AU  - Robinson,N
AU  - Sanders,H
AU  - Serrano,S
AU  - Tipton,T
AU  - Waters,A
AU  - Zacharopoulou,P
AU  - Barnes,E
AU  - Dunachie,S
AU  - Goulder,P
AU  - Klenerman,P
AU  - Screaton,GR
AU  - Winston,A
AU  - Hill,AVS
AU  - Gilbert,SC
AU  - Carroll,M
AU  - Pollard,AJ
AU  - Fidler,S
AU  - Fox,J
AU  - Lambe,T
AU  - Frater,J
DO  - 10.1172/jci.insight.157031
EP  - 18
PY  - 2022///
SN  - 2379-3708
SP  - 1
TI  - Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
T2  - JCI Insight
UR  - http://dx.doi.org/10.1172/jci.insight.157031
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000789107300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://insight.jci.org/articles/view/157031
UR  - http://hdl.handle.net/10044/1/103605
VL  - 7
ER  -
Download